[go: up one dir, main page]

FR14C0020I1 - Compositions pharmaceutiques contenant du fentanyl pour application nasale - Google Patents

Compositions pharmaceutiques contenant du fentanyl pour application nasale

Info

Publication number
FR14C0020I1
FR14C0020I1 FR14C0020C FR14C0020C FR14C0020I1 FR 14C0020 I1 FR14C0020 I1 FR 14C0020I1 FR 14C0020 C FR14C0020 C FR 14C0020C FR 14C0020 C FR14C0020 C FR 14C0020C FR 14C0020 I1 FR14C0020 I1 FR 14C0020I1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
compositions containing
nasal application
containing fentanyl
fentanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0020C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Archimedes Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9950919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0020(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Archimedes Development Ltd filed Critical Archimedes Development Ltd
Publication of FR14C0020I1 publication Critical patent/FR14C0020I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
FR14C0020C 2003-01-10 2014-03-13 Compositions pharmaceutiques contenant du fentanyl pour application nasale Active FR14C0020I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300531.1A GB0300531D0 (en) 2003-01-10 2003-01-10 Pharmaceutical compositions
PCT/GB2004/000057 WO2004062561A2 (fr) 2003-01-10 2004-01-12 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
FR14C0020I1 true FR14C0020I1 (fr) 2014-04-18

Family

ID=9950919

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0020C Active FR14C0020I1 (fr) 2003-01-10 2014-03-13 Compositions pharmaceutiques contenant du fentanyl pour application nasale

Country Status (25)

Country Link
US (5) US20040166067A1 (fr)
EP (2) EP1635783B1 (fr)
JP (1) JP4827725B2 (fr)
KR (3) KR20100118144A (fr)
CN (1) CN100423709C (fr)
AU (1) AU2004204381B2 (fr)
BR (1) BRPI0406674B8 (fr)
CA (1) CA2511974C (fr)
CY (1) CY1115056T1 (fr)
DK (1) DK1635783T5 (fr)
EA (1) EA008500B1 (fr)
ES (2) ES2432119T3 (fr)
FR (1) FR14C0020I1 (fr)
GB (1) GB0300531D0 (fr)
GE (1) GEP20084340B (fr)
IL (1) IL169480A (fr)
MX (1) MXPA05007333A (fr)
NO (1) NO335127B1 (fr)
NZ (1) NZ541018A (fr)
PL (1) PL212950B1 (fr)
PT (2) PT1635783E (fr)
SI (1) SI1635783T1 (fr)
UA (1) UA85050C2 (fr)
WO (1) WO2004062561A2 (fr)
ZA (1) ZA200505274B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05420B1 (et) * 2000-07-31 2011-06-15 Nycomed Danmark A/S Fentanli kompositsioon ninasiseseks manustamiseks
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP2057982A1 (fr) 2007-11-09 2009-05-13 Archimedes Development Limited Compositions intranasales
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
BR112013019834A2 (pt) 2011-02-04 2016-10-11 Archimedes Dev Ltd recipiente aprimorado
CN107260672A (zh) 2011-05-13 2017-10-20 欧洲凯尔特公司 包含纳洛酮的鼻内药物剂型
CA2886270C (fr) 2012-10-03 2020-04-07 Proponent Biotech Gmbh Esters d'acides gras a chaines courtes pour l'utilisation dans le traitement de troubles immunogenes
RU2731713C2 (ru) 2013-09-05 2020-09-08 Аб2 Био Са Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3265807A1 (fr) 2015-03-05 2018-01-10 AB2 Bio SA Protéine de liaison à l'il-18 (il-18 bp) et anticorps dans des maladies inflammatoires
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
SMT202400008T1 (it) * 2017-01-11 2024-03-13 Torrent Pharmaceuticals Ltd Composizione nasale con tapentadolo
US11207309B2 (en) 2019-07-19 2021-12-28 Hikma Pharmaceuticals International Limited Ready-to-administer fentanyl formulations
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
CN111272860B (zh) 2020-03-16 2022-11-25 中国检验检疫科学研究院 一种芬太尼类物质的小型便携式质谱现场快速检测方法
WO2021224432A1 (fr) 2020-05-06 2021-11-11 Ab2 Bio Sa Protéine de liaison à il-18 (il-18bp) dans des maladies inflammatoires
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (fr) 2020-07-24 2022-01-26 AB2 Bio SA Thérapie à base de cellules car t
WO2023067348A1 (fr) 2021-10-21 2023-04-27 Biosirius Ltd Traitement de la pneumonie induite par un virus
EP4486367A1 (fr) 2022-03-04 2025-01-08 AB2 Bio SA Protéine de liaison à il-18 (il-18bp) dans le traitement du syndrome vexas

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) * 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) * 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
BE623427A (fr) * 1961-10-10
US3184600A (en) 1963-05-07 1965-05-18 Potter Instrument Co Inc Photosensitive apparatus for measuring coordinate distances
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
HU193780B (en) * 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) * 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (fr) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0491076A1 (fr) 1990-12-19 1992-06-24 Theratech, Inc. Augmentation de la pénétration avec un système à composants multiples contenant des pyrrolidones N-aliphatiques avec des alcools inférieurs
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE69222295T2 (de) 1992-05-26 1998-04-09 The Procter & Gamble Co., Cincinnati, Ohio Pulverförmige pharmazeutische Zusammensetzung
AU4585493A (en) 1992-07-23 1994-02-14 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and drug composition prepared therefrom
AU5551394A (en) 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
DK0865789T3 (da) 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af dihydroergotamin
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
SE9301877D0 (sv) 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
WO1995002416A1 (fr) 1993-07-12 1995-01-26 Virus Research Institute Vaccins microencapsules sur une base d'hydrogel
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
ATE180971T1 (de) * 1994-03-30 1999-06-15 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
WO1995028914A1 (fr) 1994-04-21 1995-11-02 Hisamitsu Pharmaceutical Co., Inc. Composition de base administree par voie percutanee et composition medicamenteuse administree par voie percutanee obtenue a partir de cette derniere
JP3911290B2 (ja) * 1994-05-13 2007-05-09 アラダイム コーポレーション エアゾールを含む麻酔用処方
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
FR2733420B1 (fr) 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
DK0836511T3 (da) 1995-06-05 2004-08-09 Alza Corp Anordning for transdermal elektrotransportafgivelse af fentanyl og sufentanil
IE960375A1 (en) 1995-06-05 1996-12-11 Alza Corp Device for transdermal electrotransport delivery of fentanyl¹and sufentanil
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19527411A1 (de) * 1995-07-27 1997-01-30 Ackermann & Schmitt Gmbh & Co Kupplung
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
CA2257860A1 (fr) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Compose d'inclusion contenant un agoniste selectif de la serotonine a structure indole
US6667279B1 (en) 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
JP4754067B2 (ja) 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
AU5305899A (en) 1998-08-26 2000-03-21 Teijin Limited Powdery pernasal compositions
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
WO2000047203A1 (fr) 1999-02-12 2000-08-17 Mqs, Inc. Formulation et systeme pour administration intra-orale de principes actifs
JP2000229859A (ja) 1999-02-12 2000-08-22 Teijin Ltd 安定なブプレノルフィン経鼻製剤
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
CA2381860C (fr) * 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrice adherant a la muqueuse nasale
JP2001089359A (ja) 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GEP20053614B (en) 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
AU4341401A (en) 2000-03-10 2001-09-24 Durect Corp Opioid formulations
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
EP1296649A2 (fr) 2000-06-22 2003-04-02 Pharmasol Limited Compositions pharmaceutiques comprenant un analgesique opioide
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
EE05420B1 (et) * 2000-07-31 2011-06-15 Nycomed Danmark A/S Fentanli kompositsioon ninasiseseks manustamiseks
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB2378383A (en) 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
IL169480A (en) 2013-10-31
WO2004062561A3 (fr) 2004-10-07
KR20050103275A (ko) 2005-10-28
BRPI0406674B1 (pt) 2015-12-22
EP1635783A2 (fr) 2006-03-22
ES2432119T3 (es) 2013-11-29
BRPI0406674B8 (pt) 2021-05-25
EP1635783B1 (fr) 2013-09-18
NO20053119L (no) 2005-08-03
KR101012148B1 (ko) 2011-02-07
US20080153879A1 (en) 2008-06-26
EP2436375A1 (fr) 2012-04-04
HK1088555A1 (en) 2006-11-10
US20120270903A1 (en) 2012-10-25
AU2004204381A2 (en) 2004-07-29
AU2004204381B2 (en) 2010-11-25
KR20090058596A (ko) 2009-06-09
PL377823A1 (pl) 2006-02-20
ES2721899T3 (es) 2019-08-06
DK1635783T5 (da) 2014-05-12
CN1723012A (zh) 2006-01-18
PT2436375T (pt) 2019-05-24
EA008500B1 (ru) 2007-06-29
NO20053119D0 (no) 2005-06-24
GEP20084340B (en) 2008-03-25
GB0300531D0 (en) 2003-02-12
EP2436375B1 (fr) 2019-02-27
SI1635783T1 (sl) 2013-11-29
IL169480A0 (en) 2007-07-04
US20040166067A1 (en) 2004-08-26
US9814705B2 (en) 2017-11-14
US9078814B2 (en) 2015-07-14
KR20100118144A (ko) 2010-11-04
UA85050C2 (ru) 2008-12-25
US8216604B2 (en) 2012-07-10
CA2511974A1 (fr) 2004-07-29
JP4827725B2 (ja) 2011-11-30
DK1635783T3 (da) 2013-10-14
PT1635783E (pt) 2013-10-29
US20150283123A1 (en) 2015-10-08
BRPI0406674A (pt) 2005-12-20
NZ541018A (en) 2008-07-31
ZA200505274B (en) 2014-09-25
US8889176B2 (en) 2014-11-18
JP2006516272A (ja) 2006-06-29
PL212950B1 (pl) 2012-12-31
MXPA05007333A (es) 2006-02-17
WO2004062561A2 (fr) 2004-07-29
NO335127B1 (no) 2014-09-22
CA2511974C (fr) 2011-03-01
US20120277267A1 (en) 2012-11-01
EA200501105A1 (ru) 2005-12-29
CY1115056T1 (el) 2016-12-14
CN100423709C (zh) 2008-10-08
AU2004204381A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
FR14C0020I1 (fr) Compositions pharmaceutiques contenant du fentanyl pour application nasale
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
EP1506786A4 (fr) Compositions medicinales contenant de la ghreline
FR2851470B1 (fr) Composition pharmaceutique pour administration transdermique ou transmuqueuse
EP2100610A4 (fr) Composition pharmaceutique contenant de l'hydroxypropylcellulose faiblement substituée
FR15C0037I2 (fr) Compositions monodisperses contenant du naloxol pegyle
EP1962827A4 (fr) Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la métformine
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
SK4070U (sk) Farmaceutická kompozícia na riadené uvoľňovanie účinných látok
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
EP2028936A4 (fr) Compositions et procedes pour une potentialisation d'antibiotiques et des decouvertes de medicaments
EP1925319A4 (fr) Compositions pharmaceutiques contenant du sc(fv)2
EP1425019A4 (fr) Composition pharmaceutique
FR2844975B1 (fr) Contenant pour cosmetiques
DK1587478T3 (da) Farmaceutisk sammensætning
MA28078A1 (fr) Produits pharmaceutiques contenant des bisphosphonates
EP1970076A4 (fr) Composition pharmaceutique pour application ungueale
EP1648474A4 (fr) Methodes et compositions pharmaceutiques pour cicatriser des lesions
IS7458A (is) Stöðug lyfjablanda sem inniheldur þátt VIII
EP1602366A4 (fr) Timbre transdermique pour l'administration de medicaments ioniques
EP1819323A4 (fr) Composition pharmaceutique renfermant un agent d'anti-nucleation
FR2901273B1 (fr) Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
EP1941896A4 (fr) Composition contenant un dipeptide pour administration orale
EP1830831A4 (fr) Formulations pharmaceutiques contenant des sels de gallium
EP2263671A4 (fr) Composition pharmaceutique contenant un dérivé d'amide